{"id":"W4220811973","doi":"10.1158/1538-7445.sabcs21-p2-13-07","title":"Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada); Jewish General Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pertuzumab; Vinorelbine; Capecitabine; Trastuzumab; Internal medicine; Tolerability; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Toxicity; Phases of clinical research; Chemotherapy; Adverse effect; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008305736,0.0007592512,0.001091764,0.0003735203,0.0003125839,0.0006170457,0.0006579561,0.0007136165,0.004774282],"category_scores_gemma":[0.0003531144,0.0003246299,0.000746146,0.0003938145,0.0005157135,0.0004840175,0.0002596358,0.001839432,0.0009962949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007581724,"about_ca_system_score_gemma":0.001390426,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001695137,"about_ca_topic_score_gemma":0.00459659,"domain_scores_codex":[0.9997554,0.00009325999,0.00001980708,0.00004321064,0.00003874027,0.00004961823],"domain_scores_gemma":[0.9997798,0.0000259269,0.00005200493,0.0000159944,0.00002294269,0.0001035078],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4149151,0.06752972,0.01101033,0.00238879,0.002623083,0.0006274118,0.000294421,0.002817748,0.2651882,0.000404849,0.01309654,0.2191038],"study_design_scores_gemma":[0.314022,0.5971872,0.03358926,0.000127224,0.001980489,0.0009885962,0.00009775256,0.001682207,0.03691047,0.0001814275,0.01319162,0.00004164869],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876695,0.004346473,0.0006858727,0.000393965,0.00007905575,0.001965233,0.002210237,0.000122254,0.002527376],"genre_scores_gemma":[0.9831758,0.003806952,0.001916437,0.0006274822,0.0001039259,0.00126713,0.00489153,0.00004105989,0.004169637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004774282,"threshold_uncertainty_score":0.01597154,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08425191162979943,"score_gpt":0.4665428208257864,"score_spread":0.382290909195987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}